Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CPS1 | P31327 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16009932 | 1.00 | TSHR (0.39) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL28572878 | 1.00 | TSHR (0.39) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL20279557 | 0.88 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL17061934 | 0.86 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL21354258 | 0.86 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL17061936 | 0.86 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL28742997 | 0.85 | TSHR (0.39) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL28915023 | 0.85 | TSHR (0.39) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL28915964 | 0.85 | TSHR (0.39) | TSHRLMNAALOX15HSD17B10L3MBTL1 | |
| SCHEMBL4150920 | 0.84 | TSHR (0.41) | TSHRLMNAALOX15HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335848-A2 | DUAL MAGL AND FAAH INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-116655599-A | Synthesis and application of EGFR allosteric inhibitors | 江南大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-112996784-B | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115322158-A | As KRAS G12C Substituted quinazoline compounds of protein inhibitor | 江南大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-114656411-A | Polysubstituted quinazoline compound serving as EGFR/HER2 double-target-point inhibitor and application thereof | 江南大学 | 2022-06-24 | — | — | CN | disclosed |
| EP-3342770-B1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2022-03-30 | — | — | EP | disclosed |
| US-20210386734-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2021-12-16 | — | — | US | disclosed |
| US-11129827-B2 | Dual MAGL and FAAH inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| CN-112996784-A | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-111675700-A | Preparation method of novel anti-cancer drug AZD3759 | 通化师范学院 | 2020-09-18 | — | — | CN | disclosed |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2018-01-18 | — | — | US | disclosed |
| EP-2964638-B1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2017-08-09 | — | — | EP | disclosed |
| US-9718806-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160340342-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9375432-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2016-06-28 | — | — | US | disclosed |
| EP-2964638-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | Astrazeneca AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| US-20150320751-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | US | disclosed |
| US-9066979-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014135876-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2014-09-12 | — | — | WO | disclosed |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320751-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ABL1, ERBB2 | TSHR 2333/4885LMNA 4507/4885ALOX15 4756/4885 |
| US-11129827-B2 | Dual MAGL and FAAH inhibitors | FAAH, FAAH2, MAG | TSHR 4210/4885LMNA 3319/4885ALOX15 229/4885 |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | EGFR, ERBB2, ABL1 | TSHR 2224/4885LMNA 4179/4885ALOX15 4638/4885 |
| US-20160340342-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | EGFR, ABL1, ERBB2 | TSHR 2333/4885LMNA 4507/4885ALOX15 4756/4885 |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ERBB2, ABL1 | TSHR 2349/4885LMNA 4463/4885ALOX15 4641/4885 |
| US-20210386734-A1 | DUAL MAGL AND FAAH INHIBITORS | FAAH, FAAH2, MAG | TSHR 4210/4885LMNA 3319/4885ALOX15 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.